Investor Presentaiton

1Q20: Consolidated Income Statement Highlight Full Year Quarter 1 2019 2020 % Chg. Net sales 125,286 138,135 10% 2018 541,937 2019 532,573 %Chg. -2% Gross Profit Margin 14.1% 18.3% 12.1% 14.3% EBITDA 11,585 19,224 66% EBITDA Margin 9.2% 13.9% 39,559 7.3% 47,551 20% 8.9% EBIT 5,979 12,355 107% 17,151 24,515 43% EBIT Margin 4.8% 8.9% 3.2% 4.6% G/L on FV of Biological Assets Share in Profit of Associates Financial Costs (1,431) 2,348 (3,414) (1,762) 23% 3,974 3,235 - 19% 2,680 14% (3,665) 7% 8,343 (11,703) 8,893 7% (13,785) 18% Income Taxes Expense (687) (1,996) 191% NET PROFIT 4,279 6,111 43% (6,212) 15,531 (5,446) 18,456 - 12% 19% EPS (THB) # of capital shares Paid-Up Capital Dividend (THB/Share) 0.50 0.73 8,185 8,185 8,611 8,611 1.82 2.18 8,185 8,185 8,611 8,611 0.65 0.70 Note: (1) # of capital shares = No. of the weighted-avg. shares (2) One time expense from the amendment of the Thailand's Labour Protection Act in the amount of THB 2, 126 m in 2019 (3) Financial costs includes impact from the adoption of TFRS 16, interest on lease liabilities in the amount of THB 629 m in 1020 P.13

View entire presentation